



tellco

Pension solutions. Banking. Real estate.

Tellco Ltd
Bahnhofstrasse 4
Postfach 713
CH-6431 Schwyz

t +41 58 442 40 00
bank@tellco.ch
tellco.ch

Tellco Classic - Best Idea AtonRâ

November 2019

Description


The Tellco Classic Best Idea AtonRâ fund aims at a long-term appreciation of invested capital, by investing in listed equities issued by companies whose expected growth is a multiple of global GDP growth, thanks to innovations primarily, and without limitation, in the technology, healthcare and energy fields. The fund is managed actively on the ground of constant research in industry fundamentals and innovations in those fields, with the purpose of identifying attractive growth themes. This work is complemented by fundamental equity analysis to pick those companies which are positioned to make the most of these growth themes, coming from both developed and emerging markets.

Key data

Assets	CHF 39'933'075	
Share classes	V	R
ISIN	CH0442770316	CH0442615701
Minimum investment	CHF 100'000	none
NAV	99.86	108.07
Reference currency	CHF	
Appropriation of profit	reinvesting	
Valuation frequency	daily	
Value date	subscription/redemption plus 3 days	
Issue commission	0.00%	
Redemption commission	0.00%	
Administration fee	1.30%	
Outperformance Fee	15.00%	
High Watermark	yes	
Asset manager	Tellco Ltd., Schwyz	
Auditors	Grant Thornton Ltd., Zurich	
Benchmark	MSCI AC World CHF	

Currency allocation in %	Fund	Benchmark
USD	84.83	55.94
EUR	7.21	9.44
CHF	1.83	2.70
JPY	4.96	7.27
DKK	1.17	0.53

Indexed net performance (in CHF) as of 30.11.2019



These figures relate to the past. Past performance is no guarantee for future results. The performance after November 5th, 2018 (launch of the fund) reflects the actual performance of the fund. Performance data between April 20th, 2017 and November 5th, 2018 reflect the performance of a managed account with the same strategy, adjusted for the current fee structure of the fund. Performance data before April 20th, 2017 is based on a simulated paper portfolio with the same strategy than the fund, adjusted for the current fee structure of the fund.

Performance

in %	1 month	3 month	YTD	1 year	3 years p.a.	since inception
Fund	2.03	0.96	17.66	2.81	18.84	109.24
Benchmark	3.81	8.48	24.39	13.78	11.27	46.11

Statistical data in %

	Fund	Benchmark
Volatility 1 year	21.71	16.94
Volatility 3 years	18.88	11.71
Tracking error 1 year	9.22	
Tracking error 3 years	12.60	
Value at risk (confidence level 95%)	10.10	
Sharpe ratio (1 year/ base 0%)	0.13	0.81
Correlation 1 year	0.92	1.00

The statistical data is calculated based on data from previous months.

Top-5 positions in %

Square-A	4.88
Insulet Rg	3.86
BioTelemetry Rg	3.79
Splunk Rg	3.64
Vertex Pharmaceu Rg	3.34

Performance in %

	Jan	Feb	March	April	May	June	July	Aug	Sep	Oct	Nov	Dec	Year	BM
2019	13.61	4.62	-1.12	2.60	-5.87	4.51	3.35	-4.92	-1.68	0.64	2.03		17.66	24.39
2018	7.80	-1.08	-1.79	2.48	5.41	0.51	3.31	7.50	2.52	-14.44	-1.04	-12.62	-4.21	-8.57
2017	3.98	8.07	3.57	1.86	4.81	-1.38	7.20	3.69	1.66	7.84	0.63	-3.73	44.64	18.66

Disclaimer

General: Purchases of collective investment schemes are based on the prevailing version of the sales prospectus, fund contract as well as the Key Investor Information Document ("KIID"), in so far as these are available, in connection with the most recent annual or – where available – semi-annual report of the fund. The relevant documents can be obtained from 1741 Fund Solutions Ltd. (hereinafter "1741"). Exclusion of liability: This document was produced by 1741. However, 1741 provides no warranty or guarantee for its content or completeness and accepts no responsibility for losses or damages of any kind that arise directly or indirectly from the use of this document or the information contained herein. The opinions expressed in this document are those of 1741 at the time the document was prepared and may change at any time and without notification. Unless otherwise stated, all figures are unaudited. For information purposes only: This document is provided for information purposes only and constitutes neither investment advice, nor an offer, nor a recommendation to buy financial instruments, nor does it exempt the recipient from the use of his own judgement. Audience: This document and all information within this document are not directed at any person, who qualifies as US person in accordance with Regulation S of the US Securities Act of 1933 as amended. Neither this document, nor any copy thereof may be sent to or taken into the United States or distributed in the United States or to a US person. Condition of use: This document and the information contained therein is intended solely for persons that may access the information in accordance with the legal and regulatory provisions of both their country of residence and their country of nationality. When in doubt, we recommend that you contact a local distribution office or credit institute. Performance: Every investment is associated with risks, especially with regard to fluctuations in value and return. Positive performance in the past or an indication of such is no guarantee of positive performance in the future. Collective capital investments are volatile and can also result in the total loss of the invested capital and any income. The performance data do not take account of the costs and commissions levied on subscriptions and redemptions of fund shares. Further, no guarantee can be given that the fund's performance will reach or exceed that of the benchmark. Positive performance in the past or an indication of such is no guarantee of positive performance in the future. Investments in foreign currencies are exposed to currency fluctuations, and there is further risk that the foreign currency will decrease in value against the investor's reference currency. Distribution in Switzerland: This collective investment scheme may be distributed to qualified investors domiciled in Switzerland.